Dr. Amy Armstrong, MD
Claim this profileWashington University School of Medicine
Studies Relapse
Studies Osteosarcoma
26 reported clinical trials
58 drugs studied
About Amy Armstrong, MD
Education:
- Received an MD from Washington University School of Medicine.
Experience:
- Serves as a Pediatric Oncologist at Washington University Physicians, with a focus on oncology and pediatric cancer.
- Practices at St. Louis Children's Hospital and St. Louis Children's Specialty Care Center – West County.
- Engaged in providing a comprehensive range of clinical services, including access to innovative treatments and clinical trials.
- Collaborates with a school liaison to support the educational needs of patients during their treatment journey.
Area of expertise
1Relapse
Stage IV
Stage III
MMR negative
2Osteosarcoma
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Amy Armstrong, MD is currently running
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
Sirolimus + Chemotherapy
for High-Risk Pediatric Cancers
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Recruiting3 awards Phase 2
More about Amy Armstrong, MD
Clinical Trial Related2 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Amy Armstrong, MD has experience with
- Carboplatin
- Cyclophosphamide
- Paclitaxel
- Etoposide
- Gemcitabine
- Pembrolizumab
Breakdown of trials Amy Armstrong, MD has run
Relapse
Osteosarcoma
Soft Tissue Sarcoma
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Amy Armstrong, MD specialize in?
Is Amy Armstrong, MD currently recruiting for clinical trials?
Are there any treatments that Amy Armstrong, MD has studied deeply?
What is the best way to schedule an appointment with Amy Armstrong, MD?
What is the office address of Amy Armstrong, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.